Carregant...
Biosimilar Trastuzumab in Clinical Trials: Differences or Not?
In the last decade, cancer therapies have increasingly taken the form of combination treatments in which biologic agents play a crucial role. In breast cancer, the treatment strategy is adjusted to intrinsic subtypes such as human epidermal growth factor receptor-2(HER2)-positive. With the introduct...
Guardat en:
| Publicat a: | Breast Care (Basel) |
|---|---|
| Autor principal: | |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
S. Karger GmbH
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6465702/ https://ncbi.nlm.nih.gov/pubmed/31019438 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000496503 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|